MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote
- Sector Info (List of indian pharma Stocks)
- Indian Pharma Stocks
Indian Pharma
Stocks 
Here are the latest stock price details of India's top Indian Pharma stocks. For more detailed updates, read our Indian Pharma sector report and check the latest Indian Pharma sector results. Also check out Equitymaster's powerful stock screener to find the top pharma companies in India.
Discover: The 5-Minute Blueprint for Becoming a ONE STOCK CROREPATI
| SCRIP | BSE PRICE (Rs) | NSE PRICE (Rs) | CHART | MORE INFO |
|---|---|---|---|---|
| AARTI DRUGS | 405.85 1.83% | 406.35 1.85% |
|
More Info
|
| AJANTA PHARMA | 1,186.40 -0.38% | 1,187.00 -0.57% |
|
More Info
|
| ALEMBIC PHARMA | 745.60 2.30% | 745.75 2.10% |
|
More Info
|
| BIOCON | 321.00 0.06% | 321.05 0.02% |
|
More Info
|
| CIPLA | 937.90 -0.84% | 937.75 -0.83% |
|
More Info
|
| DIVIS LABORATORIES | 3,679.25 0.90% | 3,679.00 0.94% |
|
More Info
|
| DR. REDDYS LAB | 4,352.00 -0.95% | 4,350.10 -0.91% |
|
More Info
|
| GLENMARK PHARMA | 389.65 0.19% | 390.00 0.17% |
|
More Info
|
| INDOCO REMEDIES | 375.45 -0.35% | 376.45 0.01% |
|
More Info
|
| IPCA LABS | 953.60 1.02% | 955.00 1.16% |
|
More Info
|
| J.B.CHEMICALS | 1,595.95 0.02% | 1,593.80 -0.12% |
|
More Info
|
| LUPIN | 631.55 0.23% | 631.35 0.22% |
|
More Info
|
| NATCO PHARMA | 631.95 -1.22% | 631.55 -1.21% |
|
More Info
|
| NIFTY 50 | Not Listed | 16,109.15 0.75% |
|
More Info
|
| ORCHID PHARMA | 280.00 1.39% | 282.00 2.25% |
|
More Info
|
| PANACEA BIOTECH | 129.55 0.08% | 129.80 0.31% |
|
More Info
|
| PIRAMAL ENTERPRISES | 1,725.00 0.81% | 1,725.95 0.77% |
|
More Info
|
| S&P BSE HEALTHCARE | 22,056.08 0.55% | Not Listed |
|
More Info
|
| S&P BSE SENSEX | 54,144.06 0.73% | Not Listed |
|
More Info
|
| STRIDES PHARMA SCIENCE | 337.30 -0.25% | 337.70 -0.38% |
|
More Info
|
| SUN PHARMA | 845.85 0.97% | 845.55 0.94% |
|
More Info
|
| TORRENT PHARMA | 2,943.85 1.55% | 2,940.90 1.43% |
|
More Info
|
| WOCKHARDT | 208.50 1.16% | 208.50 1.14% |
|
More Info
|
| ZYDUS LIFESCIENCES | 366.30 0.10% | 366.75 0.26% |
|
More Info
|
BSE prices: July 7, 2022 01:15:00 PM NSE prices: July 7, 2022 1:14:59 PM
Indian Pharma Stocks Update
The NIFTY PHARMA Index was at 12,391.4 (up 0.5%). The index is down 0.2% over the last 30 days. And over the last 1 year, it has lost 14.7%.
Within the Indian Pharma sector, the top gainers were ALEMBIC PHARMA (up 2.3%) and AARTI DRUGS (up 1.8%). On the other hand, NATCO PHARMA (down 1.2%) and DR. REDDYS LAB (down 1.0%) were among the top losers.
Meanwhile, the benchmark NIFTY 50 was at 16,109.2 (up 0.8%).
What else is happening in the markets today? Dig in...
- TRACK NOW:
- Most Active Stocks Rs 0 to 10
- Most Active Stocks Rs 10 to 20
- Top Gainers Today BSE A Group
- Top Gainers Today NSE Above Rs 20
- Top Gainers Today BSE Above Rs 20
- Top Gainers Today BSE Sensex
- Top Gainers Today BSE Small Cap
- Top Gainers Today BSE 500
- Top Losers Today BSE A Group
- Most Active Stocks Rs 1 to 2
- Top Losers Today NSE Above Rs 20
- Buzzing Stocks Today
- Most Popular Stocks BSE 30
Today's Market
Sensex Zooms 400 Points, Nifty Trades Above 16,000; Titan Rallies 6%(10:30 am)
Asian share markets mostly opened higher today after minutes from a Federal Reserve meeting showed that US central bankers are determined to fight inflation despite recession worries.
Related Views on News
TORRENT PHARMA 2021-22 Annual Report Analysis (Annual Result Update)
Jul 6, 2022Here's an analysis of the annual report of TORRENT PHARMA for 2021-22. It includes a full income statement, balance sheet and cash flow analysis of TORRENT PHARMA. Also includes updates on the valuation of TORRENT PHARMA.
Pharma Company to Issue Bonus Shares this Week. Are you Eligible? (Views On News)
Jul 4, 2022The company has also announced a final dividend of Rs 23 per equity share recently.
5 Takeaways from Sun Pharma's Q4 Results (Views On News)
May 30, 2022It came as a surprise to everyone when Sun Pharma reported a consolidated net loss in Q4 instead of a profit.
3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)
Nov 9, 2021In 2021, R&D of pharma companies roared to life in a never-before-seen way.
Nifty Pharma Index - Bulls are Losing the Ground (Views On News)
Mar 16, 2022For the Nifty pharma index, it seems as if bulls are losing ground as they witness multiple bearish candlestick patterns.
More Views on NewsMost Popular
5 Indian Companies where Mutual Fund Holdings are Consistently Increasing (Views On News)
Jul 1, 2022Mutual funds are buying shares at a time when FIIs are consistently selling. Here are 5 stocks where MF holdings has increased for the past 4 quarters.
Auto Stocks are in the Fast Lane. Is it Time to Buy? (Profit Hunter)
Jun 23, 2022The auto index is outperforming the Nifty by a mile. Have auto stocks finally bottomed out?
Forget FIIs. Follow These Experts to Navigate the Market (Profit Hunter)
Jun 24, 2022How you deal with the recent correction is going to be a great differentiator in your net worth.
Why Crude Oil Price is Falling (Views On News)
Jun 25, 2022Global markets have become volatile, sending chills through the crude oil market.
The 4 Strongest Companies in the Tata Group. Add Them to Your Watchlist (Views On News)
Jun 30, 2022Check out these four Tata group companies that have the strongest performance and fundamentals.
MoreOUR TOP 5 IDEAS
S&P BSE HEALTHCARE
Jul 7, 2022 01:15 PM
S&P BSE HEALTHCARE 5-YR ANALYSIS
COMPARE COMPANY
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Multibagger Penny Stocks
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Best Small-cap Stocks to Buy
- Best Bluechip Stocks to Buy
- Guide to Penny Stocks
- How to Invest in the Share Market
- Warren Buffett - The Value Investor
- Pick the Best Multibagger Stocks in 2022
TRENDING TOPICS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.